Sector#Biotechnology - Therapeutics
Oblita Therapeutics is a global health research & development start-up company. Our goal is to close current therapeutic gaps and improve the quality of life of those suffering from “forgotten” (neglected) diseases. Oblita Therapeutics’ lead program is focused on the development of a new drug (D121) to treat leishmaniasis (starting phase II). We have convincing preclinical results on the effectiveness of D121 against Cryptosporidium Parvum infection, Chagas Disease, and Fungal Infections.
Upcoming eventsAll events
Latest newsMore news
Biotalys announces the appointment of Kevin Helash as Chief Executive Officer and Director to lead the company in its next growth phase
1 hour ago
Triple discovery unveils insights into type 2 diabetes
Thursday September 28th 2023
SwiftPharma and Medace sign strategic collaboration agreement for biomanufacturing and purification of promising medicinal proteins.
Wednesday September 27th 2023